Startups

Confluence Life Sciences

Developed small molecule kinase inhibitors for inflammatory, immunological and cancer indications, including MK-2, JAK and ITK programs. Aclaris Therapeutics acquired the company in August 2017 and retained its drug discovery and contract research teams.

Team

Jon JacobsenChemistry Director (reported at the 2017 acquisition)

Joseph MonahanFounder and CSO (reported at the 2017 acquisition)

Paul ChangelianBiology Director (reported at the 2017 acquisition)

Walter SmithCEO (reported at the 2017 acquisition)

Investments

$—Unknown date

Epidarex Capital